Aldeyra Therapeutics, Inc. (ALDX) Income Statement Analysis

See more : Ethernity Networks Ltd. (ENET.L) Income Statement Analysis – Financial Results

Complete financial analysis of Aldeyra Therapeutics, Inc. (ALDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aldeyra Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Aldeyra Therapeutics, Inc. (ALDX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.aldeyra.com

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	262.78K	258.71K	264.18K	56.22K	96.31K	71.00K	37.85K	35.79K	18.78K	0.00	0.00	0.00	0.00
Gross Profit	-262.78K	-258.71K	-264.18K	-56.22K	-96.31K	-71.00K	-37.85K	-35.79K	-18.78K	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	29.46M	47.31M	44.94M	24.68M	44.35M	29.82M	16.30M	13.18M	7.57M	3.71M	1.54M	469.27K	1.36M
General & Administrative	13.34M	15.37M	11.28M	9.99M	12.15M	9.88M	6.19M	5.52M	4.41M	3.56M	2.13M	644.94K	743.94K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	13.34M	15.37M	11.28M	9.99M	12.15M	9.88M	6.19M	5.52M	4.41M	3.56M	2.13M	644.94K	743.94K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.33M	720.79K	-21.48M	5.41K
Operating Expenses	42.79M	62.68M	56.22M	34.67M	56.51M	39.70M	22.49M	18.70M	11.99M	7.27M	3.68M	1.11M	2.11M
Cost & Expenses	42.79M	62.68M	56.22M	34.67M	56.51M	39.70M	22.49M	18.70M	11.99M	7.27M	3.68M	1.11M	2.11M
Interest Income	7.32M	2.35M	185.36K	292.22K	1.54M	952.70K	261.25K	102.04K	11.13K	3.00	31.00	101.00	5.00K
Interest Expense	2.07M	1.69M	1.74M	1.90M	603.85K	146.79K	113.45K	105.51K	112.31K	244.17K	159.32K	342.01K	279.93K
Depreciation & Amortization	262.78K	258.71K	264.18K	56.22K	96.31K	71.00K	37.85K	35.79K	18.78K	1.07K	31.00	3.74K	1.59K
EBITDA	-35.21M	-60.07M	-55.77M	-36.07M	-61.44M	-38.68M	-22.19M	-18.56M	-11.96M	-4.94M	13.22M	-22.73M	-2.10M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-42.79M	-62.68M	-56.22M	-36.42M	-63.07M	-39.70M	-22.49M	-18.70M	-11.99M	-7.27M	-3.68M	-1.11M	-2.11M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	5.25M	655.35K	-1.56M	-3.37M	-5.63M	805.91K	147.80K	-3.47K	-101.18K	2.08M	16.74M	-21.96M	-269.53K
Income Before Tax	-37.54M	-62.02M	-57.78M	-38.03M	-62.14M	-38.89M	-22.34M	-18.70M	-12.09M	-5.19M	13.06M	-23.07M	-2.38M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-655.35K	1.48M	-479.27K	-1.31M	952.70K	223.40K	66.25K	-7.65K	243.11K	159.29K	-21.14M	285.34K
Net Income	-37.54M	-61.37M	-59.25M	-37.55M	-60.83M	-38.89M	-22.34M	-18.70M	-12.09M	-5.19M	13.06M	-23.07M	-2.38M
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.64	-1.05	-1.10	-1.11	-2.24	-1.79	-1.40	-1.65	-1.40	-1.36	39.90	-5.72	-7.26
EPS Diluted	-0.64	-1.05	-1.10	-1.11	-2.24	-1.79	-1.40	-1.65	-1.40	-1.35	2.72	-5.10	-0.50
Weighted Avg Shares Out	58.94M	58.41M	54.04M	33.97M	27.11M	21.69M	15.92M	11.35M	8.63M	3.82M	327.37K	4.04M	327.37K
Weighted Avg Shares Out (Dil)	58.94M	58.41M	54.04M	33.97M	27.11M	21.69M	15.92M	11.35M	8.63M	3.85M	4.80M	4.52M	4.80M

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

May 14, 2024zacks.com

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

May 8, 2024businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical...

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024

May 3, 2024investorplace.com

Aldeyra Therapeutics (NASDAQ: ALDX ) just reported results for the first quarter of 2024. Aldeyra Therapeutics reported earnings per share of -14 cents.

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

April 25, 2024businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for...

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

April 22, 2024zacks.com

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying

April 21, 2024247wallst.com

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying

April 21, 2024247wallst.com

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

April 18, 2024businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET...

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter

April 7, 2024247wallst.com

Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.